Mod4 Research Proposal: Difference between revisions
From OpenWetWare
Jump to navigationJump to search
| Line 29: | Line 29: | ||
This study used a method similar to our proposal, but with modified bacteriophages delivering antibiotics to target bacteria. | This study used a method similar to our proposal, but with modified bacteriophages delivering antibiotics to target bacteria. | ||
*Jung J, et al. "Bio-nanocapsules for In vivo Pinpoint Drug Delivery." Yakugaku Zasshi 127.5(May 2007): 797-805. | |||
This study uses a recombinant yeast-derived hepatitis B virus surface antigen particle as a hepatitis B vaccine, but the particle can incorporate other types of materials as well. | |||
Revision as of 16:03, 3 May 2007
Project Overview
We propose a method of delivering cancer drugs, such as chemotherapy, through linkage to a virus. This virus would have a modified specificity so that it only infects cancerous mammalian cells.
Background Information
Cancer
- Cancer is one of the leading causes of death throughout the world.
- A major obstacle is cancer treatment is the lack of specificity - drugs attack cancerous cells, but they attack healthy cells as well
- Cancerous cells, such as tumors, are known to have modified surface proteins
Viruses
- Huge variety - can infect all living things
Cancer Drugs
Research Problem and Goals
Project Details and Methods
Linking drug to virus
Modifying specificity of virus
Predicted Outcomes
If all goes well, our virus should be able to deliver cancer drugs specifically to cancerous cells.
Resources
References
- Yacoby, I, et al. "Targeting antibacterial agents by using drug-carrying filamentous bacteriophages." Antimicrobial Agents and Chemotherapy 50.6(June 2006): 2087-2097.
This study used a method similar to our proposal, but with modified bacteriophages delivering antibiotics to target bacteria.
- Jung J, et al. "Bio-nanocapsules for In vivo Pinpoint Drug Delivery." Yakugaku Zasshi 127.5(May 2007): 797-805.
This study uses a recombinant yeast-derived hepatitis B virus surface antigen particle as a hepatitis B vaccine, but the particle can incorporate other types of materials as well.